Gao Yecheng, Liu Yanfang, Li Zelong, Lu Liyi, Guo Yajuan, Su Dun, Zhang Heping
Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.
Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.
mSystems. 2025 Jul 22;10(7):e0036925. doi: 10.1128/msystems.00369-25. Epub 2025 Jun 10.
Type 2 diabetes mellitus (T2DM) is a pervasive chronic metabolic disorder characterized by dysregulation of carbohydrate, protein, and lipid metabolism. The objective of this study was to elucidate the impact of multi-strain probiotic supplementation on the metabolism of carbohydrates and lipids and the interplay between the gut and liver in a T2DM rat model. A total of 32 rats were randomly assigned to four experimental groups: a control group, a T2DM model group, a low-dose probiotics group, and a high-dose probiotics group. The impact of probiotic intervention on glycemic and lipid profiles was evaluated, with a specific emphasis on the high-dose cohort. The treatment with multi-strain probiotics, consisting of three species and one species, resulted in a significant improvement in blood glucose and lipid profiles in T2DM rats, with the highest dosage demonstrating the most pronounced effects. Probiotic administration modulated gut microbiota composition and diversity, enriching potentially beneficial bacterial species and altering gut metabolic modules and carbohydrate-active enzyme profiles. Multi-omics analyses indicated that alterations in fecal short-chain fatty acids and serum bile acids may serve as pivotal mediators for crosstalk between hepatic and gut transcriptomic pathways. This study offers novel insights into the role of probiotics in managing T2DM via the gut-liver axis, emphasizing the potential of probiotic therapy in modulating key metabolic pathways.IMPORTANCEType 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, caused by defects in insulin secretion, insulin action, or both. For individuals diagnosed with T2DM, managing diabetes-related complications is often the most challenging aspect. Exogenous probiotics have the potential to serve as a promising therapeutic strategy to improve diabetes-related symptoms. We conducted a 64-day animal experiment to investigate the effects of probiotics on T2DM-related metabolic disorders and dyslipidemia by feeding four mixed probiotics to T2DM rats. The results showed that probiotics exerted beneficial effects on glucose- and lipid-related homeostasis indices in diabetic rats to some extent and modulated the gut microbiota to manage T2DM via the gut-liver axis.
2型糖尿病(T2DM)是一种普遍存在的慢性代谢紊乱疾病,其特征为碳水化合物、蛋白质和脂质代谢失调。本研究的目的是阐明在T2DM大鼠模型中,补充多菌株益生菌对碳水化合物和脂质代谢以及肠道与肝脏之间相互作用的影响。总共32只大鼠被随机分为四个实验组:对照组、T2DM模型组、低剂量益生菌组和高剂量益生菌组。评估了益生菌干预对血糖和血脂水平的影响,特别关注高剂量组。由三种和一种菌株组成的多菌株益生菌治疗使T2DM大鼠的血糖和血脂水平得到显著改善,最高剂量组的效果最为明显。益生菌给药调节了肠道微生物群的组成和多样性,富集了潜在有益细菌种类,并改变了肠道代谢模块和碳水化合物活性酶谱。多组学分析表明,粪便短链脂肪酸和血清胆汁酸的变化可能是肝脏和肠道转录组途径之间相互作用的关键介质。本研究为益生菌通过肠-肝轴管理T2DM的作用提供了新的见解,强调了益生菌疗法在调节关键代谢途径方面的潜力。重要性2型糖尿病(T2DM)是一种以高血糖为特征的慢性代谢疾病,由胰岛素分泌缺陷、胰岛素作用缺陷或两者兼而有之引起。对于被诊断为T2DM的个体,管理糖尿病相关并发症往往是最具挑战性的方面。外源性益生菌有可能成为改善糖尿病相关症状的有前景的治疗策略。我们进行了一项为期64天的动物实验,通过给T2DM大鼠喂食四种混合益生菌来研究益生菌对T2DM相关代谢紊乱和血脂异常的影响。结果表明,益生菌在一定程度上对糖尿病大鼠的血糖和脂质相关稳态指标产生了有益影响,并通过肠-肝轴调节肠道微生物群以管理T2DM。
Cochrane Database Syst Rev. 2022-9-20
Cochrane Database Syst Rev. 2025-7-10
Front Endocrinol (Lausanne). 2025-6-19
Cochrane Database Syst Rev. 2015-12-22
Naunyn Schmiedebergs Arch Pharmacol. 2024-11
World J Clin Cases. 2024-4-16
Nutrients. 2023-11-22